Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of SHR-1918 in homozygous familial hypercholesterolemia
CTR20244609Phase 3Completed
- Sponsor
- Beijing Shengdi Pharmaceutical
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-1918 in homozygous familial hypercholesterolemia (HoFH), sponsored by Beijing Shengdi Pharmaceutical. Started Dec 2024; status: completed.
02
Drugs
SHR-1918
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on CTR20244609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244609.